Clinical Trials Browser

Phase 2 × INDUSTRY × eribulin × Clear all

NCT06875128 2026-03-13

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease

Phase 2 Recruiting

Breast Neoplasms

NCT06449222 2026-02-25

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

Phase 2 Active not recruiting

Triple Negative Breast Neoplasms

NCT00879086 2023-06-22

A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer

Phase 2 Completed

104 enrolled 16 charts

Breast Neoplasms, Neoplasms

NCT01104155 2023-06-22

Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer

Phase 2 Completed

123 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT01268150 2023-06-22

A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer

Phase 2 Completed

56 enrolled 10 charts

Breast Neoplasms

NCT01269346 2023-06-22

Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer

Phase 2 Completed

52 enrolled 9 charts

Breast Neoplasms

NCT01439282 2023-06-22

Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer

Phase 2 Completed

77 enrolled 9 charts

Breast Neoplasms

NCT03441360 2022-10-05

Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Participants With Relapsed/Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)

Phase 2 Completed

23 enrolled 14 charts

Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing

NCT01328249 2019-08-20

Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer

Phase 2 Completed

81 enrolled 9 charts

Breast Neoplasms

NCT02481050 2018-11-15

Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer

Phase 2 Completed

58 enrolled 14 charts

Breast Neoplasms

NCT00246090 2014-07-14

A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine

Phase 2 Completed

298 enrolled 8 charts

Breast Neoplasms

NCT00278993 2014-07-14

Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy

Phase 2 Completed

108 enrolled 11 charts

Neoplasm Metastasis, Prostatic Neoplasms

NCT00965523 2013-08-15

Study of E7389 for Advanced or Metastatic Breast Cancer

Phase 2 Completed

81 enrolled 7 charts

Breast Neoplasms, Neoplasms

NCT00097721 2013-04-22

A Study of E7389 in Advanced/Metastatic Breast Cancer Patients

Phase 2 Completed

104 enrolled 12 charts

Breast Neoplasms

NCT00100932 2012-03-27

Phase II Study Of E7389, Halichondrin B Analogue, In Patients With Advanced Non-Small Cell Lung Cancer, NSCLC, Who Progressed During Or After Platinum-Based Doublet Chemotherapy

Phase 2 Completed

106 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung